Idelalisib Combo Rings Bells in Relapsed CLL
Patients with relapsed chronic lymphocytic leukemia, who were less able to undergo chemotherapy, had improved OS with a combination of idelalisib and rituximab, in a study reported by Dr Bruce Cheson. (Source: Medscape Oncology)
Source: Medscape Oncology - February 4, 2014 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Combination stifles CLL
The targeted therapy ibrutinib and the antibody rituximab knock down chronic lymphocytic leukemia in 90 % of patients in a clinical trial. Jan Burger, M.D., Ph.D., explains.
Author: mdanderson
Added: 12/16/2013 (Source: Oncology Tube)
Source: Oncology Tube - December 16, 2013 Category: Cancer & Oncology Source Type: podcasts
ASH 2013: Lymphoma - Rituximab maintenance therapy
Drs. Ravandi-Kashani, Czuczman, Steensma, Cortes, Anderson, and Brown comprise the faculty for this compelling group of Best of the Day interviews with Dr. Jim Epstein as moderator. These internationa...
Author: imedex
Added: 12/12/2013 (Source: Oncology Tube)
Source: Oncology Tube - December 12, 2013 Category: Cancer & Oncology Source Type: podcasts
Is there long term benefit from maintenance rituximab for lymphoma patients?
This outstanding webcast of the Lymphoma & Myeloma 2013, an International Congress on Hematologic Malignancies, includes experts presenting the current issues and clinical trial information in lym...
Author: imedex
Added: 12/03/2013 (Source: Oncology Tube)
Source: Oncology Tube - December 3, 2013 Category: Cancer & Oncology Source Type: podcasts
New Monoclonal Antibodies Adding Power to CLL Treatment
The monoclonal antibody, Rituximab, has been a backbone of CLL treatment for several years. It targets a protein on the CLL cells. Now a more powerful antibody may be available soon and has shown prom...
Author: patientpower
Added: 09/17/2013 (Source: Oncology Tube)
Source: Oncology Tube - September 17, 2013 Category: Cancer & Oncology Source Type: podcasts
An Expert's Perspective on Novel Approaches for Relapse Refractory Hodgkin Lymphoma
Dr. Stephen Ansell, a hodgkin lymphoma expert, explains exciting new treatment options for relapse refractory Hodgkin lymphoma with advancements of agents such as rituximab. As research continues, a b...
Author: patientpower
Added: 01/26/2013 (Source: Oncology Tube)
Source: Oncology Tube - January 26, 2013 Category: Cancer & Oncology Source Type: podcasts
TWiV 213: Not bad for a hobby
Hosts: Vincent Racaniello, Rich Condit, Alan Dove, and Kathy Spindler
In their final episode of the year, the TWiV team reviews twelve cool virology stories from 2012.
Twelve virology stories from 2012:
H5N1 (TWiV 190, 182, 177, 173, 168)
Polymorphisms that control susceptibility (TWiV 175, 180)
New virus receptors (TWiV 166, 210)
XMRV: Last nail in the coffin (TWiV special)
Polio eradication troubles in Pakistan (NY Times one, two, three; virology blog)
Biomedical research crisis (TWiV 208, 184, 189, 194)
Polydna...
Source: This Week in Virology - MP3 Edition - December 30, 2012 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
